

Thomas Spekschoor

ask+request-8904-791c2ce0@asktheeu.org

Stockholm, 26 January 2021

Our ref.: DPR-2021-OUT-0468-KEEIKh

Dear Mr Spekschoor,

Re: Your application for access to documents – Ref 21-0084

We refer to your e-mail dated 5 January 2021 in which you make a request for access to documents, registered on the same day under the above mentioned reference number.

I. Scope of your request

You request access to:

"- - all communication from ECDC to the Netherlands about COVID-19 vaccination strategies from October 2020 until now."

In order to satisfy your request, we ran a search through the several functional mailboxes that ECDC has dedicated to manage all the correspondence related to COVID-19, to find the correspondence from ECDC to the Netherlands by checking correspondence with email addresses ending with ".nl" about "COVID-19 vaccination strategies" from October 2020.

II. Documents that ECDC has identified

We have identified the documents listed below falling under the scope of your request. Please note that the vast majority of emails are communications between ECDC and numerous recipients, members of the EU/EEA National Immunisation Technical Advisory Groups (NITAG) collaboration, among which are included several addresses from the Netherlands.

Emails found in the mailboxes dedicated to COVID-19 and attached documents, if applicable:

1. EU NITAG COLLABORATION WEBINAR - COVID-19 vaccination models_ the need, the approach and preliminary results OCTOBER 15 14_00 - 16_00 CET

2. EU NITAG COLLABORATION Dialogue meeting on vaccination preparedness plans October 23 10:00 - 12:30 CET

2.1. Attached document: Considerations on introduction and prioritisation of COVID-19 vaccination in the EU-EEA and the UK – unpublished

The replies to the questionnaire provided by the Netherlands, among other countries, were included in a technical report, which was published on the ECDC website:

<https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines>

3. RE: EU NITAG COLLABORATION WEBINAR - COVID-19 vaccination models: the need, the approach and preliminary results OCTOBER 15 14:00 - 16:00 CET

3.1. Attached document: Health and economic impact of COVID-19 vaccination in England

3.2. Attached document: COVID-19 vaccination 20201015

3.3. Attached document: 201015 NITAG webinar

3.4. Attached document: 2020 10 15 - 16 Vaccine Prioritization

4. EU_EEA NITAG COLLABORATION WEBINAR - DOCUMENTATION OF COVID-19 VACCINATION - TUESDAY 17 NOVEMBER 14.00 - 16.30 CET

5. EU NITAG COLLABORATION Dialogue meeting on vaccination preparedness plans October 23 10_00 - 12_30 CET

5.1. Attached document: XXXXXXXX Objectives 23 Oct

5.2. Attached document: NITAG survey - COVID-19 vaccine deployment plans_KO

This is a draft document that was elaborated with information provided by the Member States back then. Therefore, it is possible that some data is not up-to-date. For this reason, we would like to provide you as well the link to the final document, which was published on the ECDC website:

<https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines>

5.3. Attached document: XXXXXXXX_Foreseen activities on COVID-19 vaccine prioritisation

5.4. Attached document: XXXXXXXX_Monitoring country preparedness

5.5. Attached document: XXXXXXXX__EMA

6. HEADS-UP PLANNED - JOINT HSC and EU-EEA NITAG COLLABORATION MEETING ON PRIORITISATION OF PRIORITY GROUPS WHEN VACCINE SUPPLY IS LIMITED

7. EU NITAG COLLABORATION Dialogue meeting on vaccination preparedness plans October 23 10_00 - 12_30 CET

7.1. Attached document: Considerations on introduction and prioritisation of COVID-19 vaccination in the EU-EEA and the UK - unpublished

7.2. Attached document: Belgium_MeetingEUNitag_23102020

7.3. Attached document: FINLAND_THL NITAG Coronavacc Strategies ECDC 20201023

7.4. Attached document: NORWAY XXXXXXXX covid-19 preparedness231020

7.5. Attached document: SLOVENIA_EU NITAG COLLABORATION – Slovenia

7.6. Attached document: Ireland COVID 19 vaccine

- 7.7. Attached document: CZECH nitag 2020 10 22
7.8. Attached document: FRANCE_ECDC Nitag_Meeting_23_10_2020
7.9. Attached document: Poland NITAG COVID-19

8. FOR YOUR REVIEW_ COVID-19 vaccination and prioritisation strategies

The document attached to this email is a draft document. For this reason, we provide you the link to the final document, which was published on the ECDC website:

<https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-and-prioritisation-strategies.pdf>

9. Summary of vaccination deployment plans for COVID-19 vaccines based on a survey and a dialogue meeting with the EU-EEA NITAG Collaboration held 23 October, 2020

The document attached to this email is a draft document. For this reason, we provide you the link to the final document, which was published on the ECDC website:

<https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines>

10. Joint HSC-EU NITAG COLLABORATION meeting Jan 6 14.30 - 16.30 - background reading_Redacted

10.1. Attached document: CEM_CMO_2020_044_JCVI_Statement (2)

10.2. Attached document: Invitation to a joint HSC_EU NITAG COLLABORATION meeting Wednesday Jan 6 14.30 - 16.30

III. Redaction of documents

The documents to which you have requested access contain personal data, in particular the name and/or contact details of authors of the documents, and/or of staff members of ECDC and/or third parties (including ECDC stakeholders or WHO staff) that are mentioned in the documents or included in a specific correspondence.

Pursuant to Article 4(1) (b) of Regulation (EC) No 1049/2001, access to a document has to be refused if its disclosure would undermine the protection of privacy and the integrity of the individual, in particular in accordance with Union legislation regarding the protection of personal data. The applicable legislation in this field is Regulation (EU) No 2018/1725.

When access is requested to documents containing personal data, Regulation (EU) No 2018/1725 becomes fully applicable. According to Article 9.1(b) of this Regulation, personal data shall only be transferred to recipients if they establish the necessity of having the data transferred to them and if there is no reason to assume that the legitimate rights of the persons concerned might be prejudiced.

We consider that, with the information available, the necessity of disclosing the aforementioned personal data to you has not been established and/or that it cannot be assumed that such disclosure would not prejudice the legitimate rights of the persons concerned. Therefore, we are disclosing the documents requested expunged from this personal data. In particular, we have redacted all the personal data of

individuals included in the documents (names, contact details, emails, images, etc.), except where the personal data is already publicly available and known.

IV. Partial disclosure of document 5.5

Having carried out a concrete and specific examination of the documents requested under the provisions of Regulation (EC) No 1049/2001 regarding public access to documents, we have come to the conclusion that document 5.5, produced by ECDC and EMA (European Medicines Agency) may be partially disclosed. Part of the document have been redacted as its disclosure is prevented by exceptions to the right of access laid down in Article 4.2 first subparagraph of this Regulation.

In this case, disclosure would undermine the commercial interests of several legal persons, as the document (slide number 2) contains sensitive commercial information about certain COVID-19 vaccines and the laboratories that have developed them. Furthermore, ECDC did not find any overriding public interest in granting a disclosure.

V. Means of redress

In accordance with Article 7(2) of Regulation (EC) No 1049/2001, you are entitled to make a confirmatory application requesting the ECDC to review this position.

Such a confirmatory application should be addressed within 15 working days upon receipt of this letter to the following address:

ECDC
Legal Services
Gustav III:s Boulevard 40
16973 Solna
Sweden

or by email to: confirmatory.requests@ecdc.europa.eu.

Yours faithfully,



Karl Ekdahl

Head of Unit Disease Programmes

Encl.: Documents 1, 2, 2.1, 3, 3.1, 3.2, 3.3, 3.4, 4, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 6, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 9, 10, 10.1, 10.2.